Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From ViiV Healthcare

HIV Market To Meet Patent Cliff In 2026-27 But Novel Products Coming

Market Snapshot: Gilead’s Biktarvy and ViiV’s two-drug regimens are expected to dominate the HIV market over the next few years as market exclusivity losses loom, but drugs with new mechanisms of action, and longer-acting products, might influence market dynamics.   

Infectious Diseases Market Intelligence

Specialty Drugs Outweighed Traditional Drug Spending For The First Time

Drugs for inflammatory conditions and cancer drove the increase in spending among the pharmacy benefit manager’s commercial plans, according to a drug trend report from Cigna's Evernorth.

Trends Immune Disorders

HIV Therapies: Maturation Inhibitor R&D Bears Fruit At ViiV Healthcare

A potent HIV maturation inhibitor has entered Phase IIb at ViiV Healthcare, in combination studies with other antiretrovirals, as the latest potential first-in-class agent to move along the company’s pipeline.

Infectious Diseases Clinical Trials

Merck & Co./Gilead Team To Take On ViiV In Long-Term HIV Treatment

The companies hope the combination of islatravir and lenacapavir will result in best-in-class oral and injectable long-term HIV products. A PrEP combo is a longer-term goal.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register